Advanced Accelerator Applications announced today at ECC 2015 that the pivotal Phase III NETTER-1 study for Lutathera (177Lu-DOTATATE) met its...
Advanced Accelerator Applications has announced that the European Commission has approved the marketing authorization of Lutathera (lutetium 177Lu oxodotreotide) for...
Novartis announced presentation of a new analysis of Lutathera (lutetium Lu 177 dotatate) NETTER-1 data examining the impact of Lutathera...
Novartis announced that the Journal of Clinical Oncology has published results of an analysis of the impact of Lutathera (lutetium...
Novartis has announced the Phase III NETTER-2 trial with Lutathera (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) met its primary endpoint
Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received FDA approval of its new drug application (NDA) for...
Novartis presented data from the Phase III NETTER-2 trial showing that Lutathera (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus long-acting release (LAR) octreotide reduced the risk of disease progression or death by 72% as first-line therapy in patients with somatostatin receptor-positive (SSTR+) well-differentiated grade 2/3 advanced gastroentero-pancreatic neuroendocrine tumors (GEP-NETs) versus high-dose octreotide LAR alone.
Lantheus Holdings, Inc. announced that its Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate (177Lu-PNT2003), a generic version of Lutathera (lutetium Lu 177 dotatate), has been accepted for filing by the FDA) marking a pivotal moment in the Company’s commitment to improve patient outcomes
Novartis reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus 30 mg octreotide LAR to 60 mg of octreotide LAR in patients with midgut neuroendocrine tumors.
Advanced Accelerator Applications announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...